Municipal Employees Retirement System of Michigan lifted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 35.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,670 shares of the specialty pharmaceutical company’s stock after buying an additional 1,470 shares during the quarter. Municipal Employees Retirement System of Michigan’s holdings in ANI Pharmaceuticals were worth $298,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its position in shares of ANI Pharmaceuticals by 91.1% in the second quarter. Dimensional Fund Advisors LP now owns 339,268 shares of the specialty pharmaceutical company’s stock worth $15,878,000 after purchasing an additional 161,743 shares during the last quarter. Vanguard Group Inc. increased its position in shares of ANI Pharmaceuticals by 8.1% in the second quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock worth $22,322,000 after purchasing an additional 35,722 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of ANI Pharmaceuticals by 7.0% in the second quarter. Renaissance Technologies LLC now owns 297,400 shares of the specialty pharmaceutical company’s stock worth $13,918,000 after purchasing an additional 19,400 shares during the last quarter. Western Standard LLC bought a new position in shares of ANI Pharmaceuticals in the second quarter worth approximately $693,000. Finally, Nationwide Fund Advisors increased its position in shares of ANI Pharmaceuticals by 267.7% in the second quarter. Nationwide Fund Advisors now owns 16,669 shares of the specialty pharmaceutical company’s stock worth $780,000 after purchasing an additional 12,136 shares during the last quarter. 55.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals, Inc. (NASDAQ ANIP) opened at $67.94 on Tuesday. ANI Pharmaceuticals, Inc. has a 52-week low of $42.23 and a 52-week high of $74.70. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 3.45. The company has a market cap of $809.07, a P/E ratio of 20.73 and a beta of 2.91.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The business had revenue of $48.16 million for the quarter, compared to analysts’ expectations of $48.12 million. During the same period last year, the business earned $1.09 earnings per share. The business’s quarterly revenue was up 25.0% on a year-over-year basis. equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.59 EPS for the current fiscal year.

Several research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a research report on Tuesday, November 7th. Canaccord Genuity reiterated a “buy” rating and set a $66.00 price target (up from $60.00) on shares of ANI Pharmaceuticals in a research report on Monday, October 16th. ValuEngine cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. BidaskClub upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Finally, TheStreet upgraded shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, November 16th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $70.50.

TRADEMARK VIOLATION NOTICE: “ANI Pharmaceuticals, Inc. (ANIP) Stake Raised by Municipal Employees Retirement System of Michigan” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/ani-pharmaceuticals-inc-anip-stake-raised-by-municipal-employees-retirement-system-of-michigan/1758731.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.